Baxter Facility Significantly Impacted by Hurricane Helene

Allocations: Baxter is implementing allocation, which limits what a customer can order based on historical purchases and medical necessity as well as available and projected inventory. Allocations help limit stockpiling and increase the likelihood of equitable access to available products, the company noted.

High-demand IV fluids: Based on Baxter’s efforts to increase manufacturing capacity at its other sites and its current assessment of anticipated timing of inbound products and air shipments, the company increased the current U.S. allocation levels of its highest-demand IV fluids for direct customers from 40% to 60%, and for distributors from 10% to 60%, effective Wednesday.

High concentration dextrose and sterile water for injection: Baxter also increased high concentration dextrose and sterile water for injection allocations and expect to be in a position to make additional increases for certain product codes by early November. Due to the vulnerable patient population they serve, allocations for IV solutions and nutrition products for designated children’s hospitals were increased to 100%.

Peritoneal dialysis supplies: Baxter said it continues to actively deliver supplies to current peritoneal dialysis (PD) patients. The company said it is working with its partners to conserve and identify alternate sources of supply across all PD product categories. In addition, the company is closely monitoring stock levels and working with partners and professional bodies to optimize utilization of PD supplies.

 Site Status: Baxter said it continues to scale production across its global locations and is working closely with FDA on temporary importation of products to increase available inventory. Based on 1) the current status of its remediation efforts, 2) its expectations regarding the company's ability to reallocate capacity from other Baxter facilities, and 3) initiation of temporary importation on certain products, the company's goal is to restart North Cove production in phases and return to 90% to 100% allocation of certain IV solution product codes by the end of 2024.